Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Retains Investment Bank to Evaluate 'Strategic Alternatives'

NEW YORK (GenomeWeb News) – Vermillion said today that it has tapped investment bank ThinkPanmure to help it identify and evaluate “strategic alternatives” for maximizing shareholder value.
 
Vermillion said it plans to work with ThinkPanmure on ways to “enhance the potential” of its OVA1 and VASCLIR proteomic tests and its pipeline of proprietary biomarkers, but added that “no assurances can be given that this evaluation will lead to any specific action or transaction.”
 
The company did not disclose further details on the strategic alternatives it is considering.
 
Vermillion in late June filed for clearance from the US Food and Drug Administration for its OVA1 ovarian tumor triage test.
 
In May, it began a clinical study to support clearance of its VASCLIR test for peripheral arterial disease.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.